EYPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EyePoint Inc (EYPT) is not a strong buy for a beginner investor seeking long-term growth at this moment. The technical indicators are neutral, options data suggests a lack of strong bullish sentiment, and the company's financial performance is weak with significant revenue decline. Additionally, recent legal disputes and negative news sentiment may weigh on the stock's performance. While analysts have raised price targets and maintain a Buy rating, the lack of strong proprietary trading signals and the absence of positive catalysts make this stock a hold for now.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 35.461, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 13.148, with resistance at 13.923 and support at 12.373.
Analysts have recently raised price targets significantly, with targets ranging from $29 to $36, reflecting optimism about the company's future prospects. The inclusion of the Phase 3 diabetic macular edema program in valuations is a positive development.
Recent lawsuits and complaints alleging false claims about the company's products and clinical findings have created negative sentiment. Additionally, the company's financial performance shows a sharp revenue decline and ongoing losses, which may deter investor confidence.
In 2025/Q4, revenue dropped significantly by -94.65% YoY to $620,000. However, net income improved to -$67.61M, up 63.31% YoY, and EPS increased to -0.81, up 26.56% YoY. Gross margin fell sharply to 39.52%, down -57.49% YoY, indicating operational challenges.
Analysts maintain a Buy rating with raised price targets ranging from $29 to $36, reflecting optimism about the company's long-term potential despite current challenges.
